| 1 |
30522358 | XPG polymorphisms and their association with lung cancer susceptibility, overall survival and response in North Indian patients treated with platinum-based doublet chemotherapy. | 2019 Jan |
1 |
| 2 |
29416691 | Chinese C allele carriers of the ERCC5 rs1047768 polymorphism are more sensitive to platinum-based chemotherapy: a meta-analysis. | 2018 Jan 2 |
2 |
| 3 |
28314991 | XPG genetic polymorphisms and clinical outcome of patients with advanced non-small cell lung cancer under platinum-based treatment: a meta-analysis of 12 studies. | 2017 Apr |
1 |
| 4 |
25729984 | XPG polymorphisms are associated with prognosis of advanced non-small cell lung cancer treated with platinum-based doublet chemotherapy. | 2015 Jan 26 |
3 |
| 5 |
26338418 | A common polymorphism in the 5' UTR of ERCC5 creates an upstream ORF that confers resistance to platinum-based chemotherapy. | 2015 Sep 15 |
2 |
| 6 |
24615519 | Genetic polymorphisms in XPG could predict clinical outcome of platinum-based chemotherapy for advanced non-small cell lung cancer. | 2014 Jun |
1 |
| 7 |
24737519 | Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer. | 2014 Mar 31 |
3 |
| 8 |
22158331 | DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer. | 2013 Apr |
1 |
| 9 |
23211354 | Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer. | 2013 Mar |
4 |
| 10 |
23621222 | XPG is predictive gene of clinical outcome in advanced non-small-cell lung cancer with platinum drug therapy. | 2013 |
3 |
| 11 |
24353624 | XPG is a novel biomarker of clinical outcome in advanced non-small-cell lung cancer. | 2013 May |
1 |
| 12 |
22781116 | [Effect of XPG down-regulation gene expression towards the proliferation of epithelial ovarian cancer cells and its chemosensitivity to platinum]. | 2012 Apr |
2 |
| 13 |
22860255 | Removal notice to: "A polymorphism in the 5' untranslated region of ERCC5 determines effectiveness of platinum-based chemotherapeutics" [Toxicology 290 (2011) 118]. | 2012 Aug 16 |
1 |
| 14 |
23118991 | Association between single nucleotide polymorphisms (SNPs) and toxicity of advanced non-small-cell lung cancer patients treated with chemotherapy. | 2012 |
1 |
| 15 |
20868484 | Down-regulation of the nucleotide excision repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells. | 2010 Sep 24 |
1 |
| 16 |
19157633 | Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. | 2009 Aug |
3 |
| 17 |
19430706 | XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer. | 2009 May |
2 |
| 18 |
18565881 | ERCC5 is a novel biomarker of ovarian cancer prognosis. | 2008 Jun 20 |
1 |